From GlobeNewswire:

Tarsus Pharmaceuticals, Inc. launched XDEMVY®, a treatment for Demodex blepharitis, with $13.1 million in net product sales in the fourth quarter and $14.7 million in the first four months. The company delivered over 17,400 bottles of XDEMVY to patients and reported positive results across their clinical portfolio.

CEO Bobak Azamian stated that Tarsus is creating a new category in eye care, with strong growth driven by the launch of XDEMVY. The company reached over 6,000 Eye Care Providers and published six manuscripts validating their study results. Positive topline data from Phase 2a trials for TP-03, TP-05, and TP-04 were also reported.



Read more at GlobeNewswire:: Tarsus Reports Strong Fourth Quarter and Full-Year 2023